Search This Blog

Thursday, August 27, 2015

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes (NYSE:LLY)

SYNJARDY approval was based on multiple clinical trials showing reductions in blood glucose versus placebo



U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.